USE OF CIRCULATING TUMOUR DNA TO CHARACTERISE THE MUTATIONAL LANDSCAPE OF MARGINAL ZONE LYMPHOMA, MONITOR TREATMENT RESPONSE AND DETECT EMERGENCE OF RESISTANCE

Abstract

Marginal zone lymphoma (MZL) is a subtype of B-cell non-Hodgkin lymphoma for which the molecular drivers of disease are poorly understood. We hypothesise that circulating tumour DNA may be ideal for characterising the genetic mutations that underpin MZL, monitoring treatment response and detecting emergence of resistance. This non-invasive method of disease monitoring has the potential to transform management of cancers such as MZL, identify new treatment options and improve survival outcomes.